|
1
|
Chacko KR and Reinus J: Spectrum of
alcoholic liver disease. Clin Liver Dis. 20:419–427. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louvet A and Mathurin P: Alcoholic liver
disease: Mechanisms of injury and targeted treatment. Nat Rev
Gastroenterol Hepatol. 12:231–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Osna NA, Donohue TM Jr and Kharbanda KK:
Alcoholic liver disease: Pathogenesis and current management.
Alcohol Res. 38:147–161. 2017.PubMed/NCBI
|
|
4
|
Sun X, Tang Y, Tan X, Li Q, Zhong W, Sun
X, Jia W, McClain CJ and Zhou Z: Activation of peroxisome
proliferator-activated receptor-gamma by rosiglitazone improves
lipid homeostasis at the adipose tissue-liver axis in ethanol-fed
mice. Am J Physiol Gastrointest Liver Physiol. 302:G548–G557. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ji C, Chan C and Kaplowitz N: Predominant
role of sterol response element binding proteins (SREBP) lipogenic
pathways in hepatic steatosis in the murine intragastric ethanol
feeding model. J Hepatol. 45:717–724. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Dou X, Li S, Zhang X, Sun X, Zhou
Z and Song Z: Nuclear factor (erythroid-derived 2)-like 2
activation-induced hepatic very-low-density lipoprotein receptor
overexpression in response to oxidative stress contributes to
alcoholic liver disease in mice. Hepatology. 59:1381–1392. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishii H, Kurose I and Kato S: Pathogenesis
of alcoholic liver disease with particular emphasis on oxidative
stress. J Gastroenterol Hepatol. 12:S272–S282. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kawaratani H, Tsujimoto T, Douhara A,
Takaya H, Moriya K, Namisaki T, Noguchi R, Yoshiji H, Fujimoto M
and Fukui H: The effect of inflammatory cytokines in alcoholic
liver disease. Mediators Inflamm: 495156. 2013. View Article : Google Scholar
|
|
9
|
Cushnie TP and Lamb AJ: Antimicrobial
activity of flavonoids. Int J Antimicrob Agents. 26:343–356. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kale A, Gawande S and Kotwal S: Cancer
phytotherapeutics: Role for flavonoids at the cellular level.
Phytother Res. 22:567–577. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meotti FC, Fachinetto R, Maffi LC, Missau
FC, Pizzolatti MG, Rocha JB and Santos AR: Antinociceptive action
of myricitrin: Involvement of the K+ and Ca2+ channels. Eur J
Pharmacol. 567:198–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qi S, Feng Z, Li Q, Qi Z and Zhang Y:
Myricitrin modulates NADPH oxidase-dependent ROS production to
inhibit endotoxin-mediated inflammation by blocking the JAK/STAT1
and NOX2/p47phox pathways. Oxid Med Cell Longev.
20147:97387452017.
|
|
13
|
Shimosaki S, Tsurunaga Y, Itamura H and
Nakamura M: Anti-allergic effect of the flavonoid myricitrin from
Myrica rubra leaf extracts in vitro and in vivo. Nat Prod
Res. 25:374–380. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu JH, Huang CY, Tung YT and Chang ST:
Online RP-HPLC-DPPH screening method for detection of
radical-scavenging phytochemicals from flowers of Acacia
confusa. J Agric Food Chem. 56:328–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen W, Feng L, Shen Y, Su H, Li Y, Zhuang
J, Zhang L and Zheng X: Myricitrin inhibits acrylamide-mediated
cytotoxicity in human Caco-2 cells by preventing oxidative stress.
Biomed Res Int: 724183. 2013. View Article : Google Scholar
|
|
16
|
Sun GB, Qin M, Ye JX, Pan RL, Meng XB,
Wang M, Luo Y, Li ZY, Wang HW and Sun XB: Inhibitory effects of
myricitrin on oxidative stress-induced endothelial damage and early
atherosclerosis in ApoE-/- mice. Toxicol Appl Pharmacol.
271:114–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qin M, Luo Y, Meng XB, Wang M, Wang HW,
Song SY, Ye JX, Pan RL, Yao F, Wu P, et al: Myricitrin attenuates
endothelial cell apoptosis to prevent atherosclerosis: An insight
into PI3K/Akt activation and STAT3 signaling pathways. Vascul
Pharmacol. 70:23–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Domitrović R, Rashed K, Cvijanović O,
Vladimir-Knežević S, Škoda M and Višnić A: Myricitrin exhibits
antioxidant, anti-inflammatory and antifibrotic activity in carbon
tetrachloride-intoxicated mice. Chem Biol Interact. 230:21–29.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Altamirano J and Bataller R: Alcoholic
liver disease: Pathogenesis and new targets for therapy. Nat Rev
Gastroenterol Hepatol. 8:491–501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qiu L, Cai C, Zhao X, Fang Y, Tang W and
Guo C: Inhibition of aldose reductase ameliorates ethanol induced
steatosis in HepG2 cells. Mol Med Rep. 15:2732–2736. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thiele DL: Tumor necrosis factor, the
acute phase response and the pathogenesis of alcoholic liver
disease. Hepatology. 9:497–499. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sid B, Verrax J and Calderon PB: Role of
AMPK activation in oxidative cell damage: Implications for
alcohol-induced liver disease. Biochem Pharmacol. 86:200–209. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
You M, Matsumoto M, Pacold CM, Cho WK and
Crabb DW: The role of AMP-activated protein kinase in the action of
ethanol in the liver. Gastroenterology. 127:1798–1808. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi C, Wang Y, Gao J, Chen S, Zhao X, Cai
C, Guo C and Qiu L: Inhibition of aldose reductase ameliorates
alcoholic liver disease by activating AMPK and modulating oxidative
stress and inflammatory cytokines. Mol Med Rep. 16:2767–2772. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hong SH, Lee H, Lee HJ, Kim B, Nam MH,
Shim BS and Kim SH: Ethanol extract of pinus koraiensis leaf
ameliorates alcoholic fatty liver via the activation of LKB1-AMPK
signaling in vitro and in vivo. Phytother Res. 31:783–791. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Neuman MG, Maor Y, Nanau RM, Melzer E,
Mell H, Opris M, Cohen L and Malnick S: Alcoholic liver disease:
Role of cytokines. Biomolecules. 5:2023–2034. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prystupa A, Kiciński P, Sak J,
Boguszewska-Czubara A, Torun-Jurkowska A and Zaluska W:
Proinflammatory cytokines (IL-1alpha, IL-6) and hepatocyte growth
factor in patients with alcoholic liver cirrhosis. Gastroenterol
Res Pract. 2015:5326152015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McClain CJ and Cohen DA: Increased tumor
necrosis factor production by monocytes in alcoholic hepatitis.
Hepatology. 9:349–351. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Endo M, Masaki T, Seike M and Yoshimatsu
H: TNF-alpha induces hepatic steatosis in mice by enhancing gene
expression of sterol regulatory element binding protein-1c
(SREBP-1c). Exp Biol Med (Maywood). 232:614–621. 2007.PubMed/NCBI
|
|
31
|
Schmidt-Arras D and Rose-John S: IL-6
pathway in the liver: From physiopathology to therapy. J Hepatol.
64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garcia D and Shaw RJ: AMPK: Mechanisms of
cellular energy sensing and restoration of metabolic balance. Mol
Cell. 66:789–800. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Viollet B, Guigas B, Leclerc J, Hébrard S,
Lantier L, Mounier R, Andreelli F and Foretz M: AMP-activated
protein kinase in the regulation of hepatic energy metabolism: From
physiology to therapeutic perspectives. Acta Physiol (Oxf).
196:81–98. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
García-Villafranca J, Guillén A and Castro
J: Ethanol consumption impairs regulation of fatty acid metabolism
by decreasing the activity of AMP-activated protein kinase in rat
liver. Biochimie. 90:460–466. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ferré P and Foufelle F: SREBP-1c
transcription factor and lipid homeostasis: Clinical perspective.
Horm Res. 68:72–82. 2007.PubMed/NCBI
|
|
36
|
Ferré P and Foufelle F: Hepatic steatosis:
A role for de novo lipogenesis and the transcription factor
SREBP-1c. Diabetes Obes Metab. 12 Suppl 2:83–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Horton JD, Goldstein JL and Brown MS:
SREBPs: Activators of the complete program of cholesterol and fatty
acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hers HG: [Aldose reductase]. Biochim
Biophys Acta. 37:120–126. 1960. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Varma SD, Mikuni I and Kinoshita JH:
Flavonoids as inhibitors of lens aldose reductase. Science.
188:1215–1216. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Veeresham C, Rama Rao A and Asres K:
Aldose reductase inhibitors of plant origin. Phytother Res.
28:317–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
